Amyloidosis is a group of diseases in which abnormal proteins, known as amyloid fibrils, build up in tissue There are several types with varying symptoms; signs and symptoms may include diarrhoea, weight loss, feeling tired, enlargement of the tongue, bleeding, numbness, feeling faint with standing, swelling of the legs, or enlargement of the spleen.

There are about 30 different types of amyloidosis, each due to a specific protein misfolding. Some are genetic while others are acquired. They are grouped into localized forms, and systemic ones. The four most common types of systemic amyloidosis are light chain (AL), inflammation (AA), dialysis-related (Aβ2M), and hereditary and old age (ATTR and familial amyloid polyneuropathy.

Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach.

Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause. AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about 2 per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment, life expectancy is between six months and four years In the developed world about 1 per 1,000 people die annually from amyloidosis. Amyloidosis has been described since at least 1639.

Causes

Many different proteins can lead to amyloid deposits, but only a few have been linked to major he have. Amyloid deposits may collect throughout your body or in just one area.

There's no cure for amyloidosis. But treatment can help manage signs and symptoms and limit further production of amyloid protein. If the amyloidosis has been triggered by another condition, such as rheumatoid arthritis or tuberculosis, treating the underlying condition can be helpful

Amyloidosis has a poor prognosis, and the median survival without treatment is only 13 months. Cardiac involvement has the worst prognosis and results in death in about 6 months after onset of congestive heart failure. Only 5% of the patients with primary amyloidosis survive beyond 10 years

Surgical Pathology and Diagnosis is a peer-reviewed medical journal published by Oxford University Press covering research on the pathogenesis, clinical investigation, medical microbiology, diagnosis, immune mechanisms, and treatment of diseases.

The Scientists, Professors, Research scholars, Doctors can publish their high quality papers for worldwide viability on our online platform. This journal is using Editorial Tracking System for online manuscript submission. Manuscript can be submitted through online portal system https://www.scholarscentral.org/submissions/surgical-pathology-diagnosis.html or send us as an e-mail attachment to surgicalpathol@emedsci.com

Best Regards

Eliza Grace

Journal Manager

Journal of Surgical Pathology and Diagnosis